ISIS 14803
Phase 2Small molecule
Ionis PharmaceuticalsISIS 14803 is one of 207 small molecule programs targeting Type 2 Diabetes Mellitus. It is currently in Phase 2.
7
Indications
21
Total Trials
0
Active Trials
206
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
791 competitors in Rheumatoid Arthritis
#DrugCompanyPhaseTrials
1Rituxan
RochePreclinical
ISIS 14803
Ionis PharmaceuticalsPhase 2
Arcoxia
NovartisPreclinical
Kevzara
AAzienda U.S.L. 1 di Massa e Carrara
Preclinical
Zelhou
Jiangsu Simcere Pharmaceutical Co., Ltd.Preclinical
Cataflam
NovartisPreclinical
Rituxan
PfizerPreclinical
Certolizumab
Johnson & JohnsonPreclinical
Disalcid
JJoslin Diabetes Center
Preclinical
Voltaren
CCerimon Pharmaceuticals
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Type 2 Diabetes Mellitus3 trials
10 more indications
End-Stage Renal Disease1 trial
Hypertriglyceridemia1 trial
Insulin Sensitivity1 trial
Carboplatin1 trial
Familial Amyotrophic Lateral Sclerosis1 trial
Huntington's Disease1 trial
End Stage Renal Disease (ESRD)1 trial
Paroxysmal atrial fibrillation1 trial
Rheumatoid Arthritis1 trial
Unspecified5 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ISIS 14803. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company